@article{MTMT:34250233,
	title = {Effectiveness and waning of protection with the BNT162b2 vaccine against the SARS-CoV-2 Delta variant in immunocompromised individuals},
	url = {https://m2.mtmt.hu/api/publication/34250233},
	author = {Szekanecz, Zoltán and Vokó, Zoltán and Surján, Orsolya and Rákóczi, Éva and Szamosi, Szilvia and Szűcs, Gabriella and Szekanecz, Éva and Müller, Cecília and Kiss, Zoltán},
	doi = {10.3389/fimmu.2023.1247129},
	journal-iso = {FRONT IMMUNOL},
	journal = {FRONTIERS IN IMMUNOLOGY},
	volume = {14},
	unique-id = {34250233},
	issn = {1664-3224},
	abstract = {Introduction
		In Hungary, the HUN-VE 3 study determined the comparative effectiveness of various primary and booster vaccination strategies during the Delta COVID-19 wave. That study included more than 8 million 18-100-year-old individuals from the beginning of the pandemic. Immunocompromised (IC) individuals have increased risk for COVID-19 and disease course might be more severe in them. In this study, we wished to estimate the risk of SARS-CoV-2 infection and COVID-19 related death in IC individuals compared to healthy ones and the effectiveness of the BNT162b2 vaccine by reassessing HUN-VE 3 data.
		Patients and methods
		Among the 8,087,988 individuals undergoing follow-up from the onset of the pandemic in the HUN-VE 3 cohort, we selected all the 263,116 patients with a diagnosis corresponding with IC and 6,128,518 controls from the second wave, before vaccinations started. The IC state was defined as two occurrences of corresponding ICD-10 codes in outpatient or inpatient claims data since 1 January, 2013. The control group included patients without chronic diseases. The data about vaccination, SARS-CoV-2 infection and COVID-19 related death were obtained from the National Public Health Center (NPHC) during the Delta wave. Cases of SARS-CoV-2 infection were reported on a daily basis using a centralized system via the National Public Health Center (NPHC).
		Results
		Out of the 263,116 IC patients 12,055 patients (4.58%) and out of the 6,128,518 healthy controls 202,163 (3.30%) acquired SARS-CoV-2 infection. Altogether 436 IC patients and 2141 healthy controls died in relation to COVID-19. The crude incidence rate ratio (IRR) of SARS-CoV-2 infection was 1.40 (95%CI: 1.37-1.42) comparing IC patients to healthy controls. The crude mortality rate ratio was 4.75 (95%CI: 4.28-5.27). With respect to SARS-CoV-2 infection, interestingly, the BNT162b2 vaccine was more effective in IC patients compared to controls. Primary vaccine effectiveness (VE) was higher in IC patients compared to controls and the booster restored VE after waning. VE regarding COVID-19 related death was less in IC patients compared to healthy individuals. Booster vaccination increased VE against COVID-19-related death in both IC patients and healthy controls.
		Conclusion
		There is increased risk of SARS-CoV-2 infection and COVID-19 related mortality in IC patient. Moreover, booster vaccination using BNT162b2 might restore impaired VE in these individuals.},
	year = {2023},
	eissn = {1664-3224},
	orcid-numbers = {Vokó, Zoltán/0000-0002-1004-1848; Kiss, Zoltán/0000-0002-4752-8529}
}

@article{MTMT:34205120,
	title = {Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience},
	url = {https://m2.mtmt.hu/api/publication/34205120},
	author = {Sebestyén, Enikő and Major, Nóra and Bodoki, Levente and Makai, Attila and Balogh, Ingrid and Tóth, Gábor and Orosz, Zsuzsanna and Árkosy, Péter and Vaskó, Attila and Hodosi, Katalin and Szekanecz, Zoltán and Szekanecz, Éva},
	doi = {10.3389/fonc.2023.1252215},
	journal-iso = {FRONT ONCOL},
	journal = {FRONTIERS IN ONCOLOGY},
	volume = {13},
	unique-id = {34205120},
	issn = {2234-943X},
	year = {2023},
	eissn = {2234-943X}
}

@article{MTMT:32634351,
	title = {Angiotensin Converting Enzyme Activity in Anti-TNF-Treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients},
	url = {https://m2.mtmt.hu/api/publication/32634351},
	author = {Soós, Boglárka and Fagyas, Miklós and Horváth, Ágnes and Végh, Edit and Karancsiné Pusztai, Anita and Czókolyová, Monika and Csongrádi, Alexandra and Hamar, Attila and Pethő, Zsófia and Bodnár, Nóra and Kerekes, György and Hodosi, Katalin and Szekanecz, Éva and Szamosi, Szilvia and Szántó, Sándor Zoltán and Szűcs, Gabriella and Papp, Zoltán and Szekanecz, Zoltán},
	doi = {10.3389/fmed.2021.785744},
	journal-iso = {FRONT MED},
	journal = {FRONTIERS IN MEDICINE},
	volume = {8},
	unique-id = {32634351},
	abstract = {Introduction: Angiotensin-converting enzyme (ACE) and ACE2 have been implicated in the regulation of vascular physiology. Elevated synovial and decreased or normal ACE or ACE2 levels have been found in rheumatoid arthritis (RA). Very little is known about the effects of tumor necrosis factor α (TNF-α) inhibition on ACE or ACE2 homeostasis. In this study, we assessed the effects of one-year anti-TNF therapy on ACE and ACE2 production in RA and ankylosing spondylitis (AS) in association with other biomarkers.
		
		Patients and Methods: Forty patients including 24 RA patients treated with either etanercept (ETN) or certolizumab pegol (CZP) and 16 AS patients treated with ETN were included in a 12-month follow-up study. Serum ACE levels were determined by commercial ELISA, while serum ACE2 activity was assessed using a specific quenched fluorescent substrate. Ultrasonography was performed to determine flow-mediated vasodilation (FMD), common carotid intima-media thickness (ccIMT) and arterial pulse-wave velocity (PWV) in all patients. In addition, CRP, rheumatoid factor (RF) and ACPA were also measured. All assessments were performed at baseline and 6 and 12 months after treatment initiation.
		
		Results: Anti-TNF therapy increased ACE levels in the full cohort, as well as in the RA and AS subsets. ACE2 activity increased in the full cohort, while the ACE/ACE2 ratio increased in the full cohort and in the RA subset (p < 0.05). Uni- and multivariable regression analyses determined associations between ACE or ACE/ACE2 ratios at different time points and disease duration, CRP, RF, FMD and IMT (p < 0.05). ACE2 activity correlated with CRP. The changes of ACE or ACE2 over 12 months were determined by treatment together with either RF or FMD (p < 0.05).
		
		Conclusions: Anti-TNF treatment may increase ACE and ACE2 in the sera of RA and AS patients. ACE and ACE2 may be associated with disease duration, markers of inflammation and vascular pathophysiology. The effects of TNF inhibition on ACE and ACE2 may reflect, in part, the effects of these biologics on the cardiovascular system.},
	year = {2022},
	eissn = {2296-858X},
	orcid-numbers = {Szántó, Sándor Zoltán/0000-0001-5030-6292}
}

@article{MTMT:32575467,
	title = {Prospective, simultaneous assessment of joint and vascular inflammation by PET/CT in tofacitinib-treated patients with rheumatoid arthritis: associations with vascular and bone status},
	url = {https://m2.mtmt.hu/api/publication/32575467},
	author = {Hamar, Attila and Hascsi, Zsolt and Karancsiné Pusztai, Anita and Czókolyová, Monika and Végh, Edit and Pethő, Zsófia and Gulyás, Katalin and Soós, Boglárka and Kerekes, György and Szekanecz, Éva and Hódosi, Katalin and Szántó, Sándor Zoltán and Szűcs, Gabriella and Seres, Tamás and Szekanecz, Zoltán and Szamosi, Szilvia},
	doi = {10.1136/rmdopen-2021-001804},
	journal-iso = {RMD OPEN},
	journal = {RMD OPEN},
	volume = {7},
	unique-id = {32575467},
	issn = {2056-5933},
	keywords = {rheumatoid arthritis; PET-CT; JAK-gátló},
	year = {2021},
	eissn = {2056-5933},
	pages = {1-10},
	orcid-numbers = {Szántó, Sándor Zoltán/0000-0001-5030-6292}
}

@article{MTMT:32501310,
	title = {SIMULTANEOUS ASSESSMENT OF JOINT AND VASCULAR INFLAMMATION BY PET-CT IN TOFACITINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS: A PROSPECTIVE STUDY},
	url = {https://m2.mtmt.hu/api/publication/32501310},
	author = {Hamar, Attila and Hascsi, Z. and Karancsiné Pusztai, Anita and Czókolyová, Monika and Vegh, E. and Pethő, Zsófia and Gulyás, Katalin and Soos, B. and Kerekes, György and Szekanecz, Éva and Hodosi, K. and Szántó, Sándor Zoltán and Szűcs, Gabriella and Seres, T. and Szekanecz, Zoltán and Szamosi, Szilvia},
	doi = {10.1136/annrheumdis-2021-eular.2473},
	journal-iso = {ANN RHEUM DIS},
	journal = {ANNALS OF THE RHEUMATIC DISEASES},
	volume = {80},
	unique-id = {32501310},
	issn = {0003-4967},
	year = {2021},
	eissn = {1468-2060},
	pages = {425-425},
	orcid-numbers = {Szántó, Sándor Zoltán/0000-0001-5030-6292}
}

@article{MTMT:32500463,
	title = {EFFECTS OF TOFACITINIB THERAPY ON ARGININE AND METHIONINE METABOLITES IN ASSOCIATION WITH VASCULAR PATHOPHYSIOLOGY IN RHEUMATOID ARTHRITIS: A METABOLOMIC APPROACH},
	url = {https://m2.mtmt.hu/api/publication/32500463},
	author = {Soos, B. and Hamar, Attila and Karancsiné Pusztai, Anita and Czókolyová, Monika and Vegh, E. and Szamosi, Szilvia and Pethő, Zsófia and Gulyás, Katalin and Kerekes, György and Szekanecz, Éva and Szántó, Sándor Zoltán and Szűcs, Gabriella and Christians, U. and Klawitter, J. and Seres, T. and Szekanecz, Zoltán},
	doi = {10.1136/annrheumdis-2021-eular.1697},
	journal-iso = {ANN RHEUM DIS},
	journal = {ANNALS OF THE RHEUMATIC DISEASES},
	volume = {80},
	unique-id = {32500463},
	issn = {0003-4967},
	year = {2021},
	eissn = {1468-2060},
	pages = {421-422},
	orcid-numbers = {Szántó, Sándor Zoltán/0000-0001-5030-6292}
}

@article{MTMT:32499606,
	title = {Peripheral quantitative computed tomography in the assessment of bone mineral density in anti-TNF-treated rheumatoid arthritis and ankylosing spondylitis patients},
	url = {https://m2.mtmt.hu/api/publication/32499606},
	author = {Juhász, Balázs and Gulyás, Katalin and Horváth, Á. and Végh, E. and Karancsiné Pusztai, Anita and Szentpetery, A. and Pethő, Zsófia and Bodnár, Nóra and Hamar, Attila and Bodoki, Levente and Bhattoa Harjit, Pál and Szekanecz, Éva and Hodosi, K. and Domjan, A. and Szamosi, Szilvia and Horváth, C. and Szántó, Sándor Zoltán and Szűcs, Gabriella and Raterman, H. and Lems, W. and Fitzgerald, O. and Szekanecz, Zoltán},
	doi = {10.1136/annrheumdis-2021-eular.1951},
	journal-iso = {ANN RHEUM DIS},
	journal = {ANNALS OF THE RHEUMATIC DISEASES},
	volume = {80},
	unique-id = {32499606},
	issn = {0003-4967},
	year = {2021},
	eissn = {1468-2060},
	pages = {226-227},
	orcid-numbers = {Bhattoa Harjit, Pál/0000-0002-4909-0065; Szántó, Sándor Zoltán/0000-0001-5030-6292}
}

@article{MTMT:32490017,
	title = {Changes of Metabolic Biomarker Levels upon One-Year Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis: Associations with Vascular Pathophysiology},
	url = {https://m2.mtmt.hu/api/publication/32490017},
	author = {Czókolyová, Monika and Karancsiné Pusztai, Anita and Végh, Edit and Horváth, Ágnes and Szentpéteri, Anita and Hamar, Attila and Szamosi, Szilvia and Hódosi, Katalin and Domján, Andrea and Szántó, Sándor Zoltán and Kerekes, György and Seres, Ildikó and Harangi, Mariann and Paragh, György and Szekanecz, Éva and Szekanecz, Zoltán and Szűcs, Gabriella},
	doi = {10.3390/biom11101535},
	journal-iso = {BIOMOLECULES},
	journal = {BIOMOLECULES},
	volume = {11},
	unique-id = {32490017},
	issn = {2218-273X},
	abstract = {Background: Cardiovascular (CV) morbidity, mortality, and metabolic syndrome are associated with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Here, lipids and other metabolic markers in relation to vascular function and clinical markers were evaluated in RA and AS patients undergoing one-year anti-TNF therapy. Patients and methods: Fifty-three patients including 36 RA patients treated with either etanercept (ETN) or certolizumab pegol (CZP) and 17 AS patients treated with ETN were included in a 12-month follow-up study. Various lipids, paraoxonase (PON) and arylesterase (ARE) activities, myeloperoxidase (MPO) and adipokine levels were determined overtime. Ultrasonography was performed to determine flow-mediated vasodilation (FMD), common carotid intima-media thickness (ccIMT), and arterial pulse-wave velocity (PWV) in all patients. All assessments were performed at baseline and 6 and 12 months after treatment initiation. Results: Anti-TNF therapy decreased ARE activity, MPO, adiponectin, and chemerin levels after 12 months (p < 0.05). Lipids, PON activity, and leptin remained unchanged. Regression analyses suggested variable associations of IMT, PWV, and FMD with ARE, MPO, leptin, and lipids (p < 0.05). On the other hand, these metabolic parameters were significantly associated with disease duration, CV history, CRP, obesity, PWV, and IMT (p < 0.05). One-year anti-TNF treatment together with baseline leptin (p = 0.039) or CRP (p = 0.016) levels determined 12 months of lipid changes overtime. TNF inhibition together with baseline disease activity determined ARE activity changes (p = 0.046). Anti TNF therapy and baseline chemerin levels determined IMT changes overtime (p = 0.003). Conclusions: Assessment of various metabolic parameters together with disease activity, CRP, and ultrasound based techniques may exert additional value in determining CV burden and in monitoring the effects of biologics on preclinical vascular pathophysiology.},
	keywords = {LIPIDS; rheumatoid arthritis; Adipokines; ankylosing spondylitis; Biologic therapy; metabolic biomarkers},
	year = {2021},
	eissn = {2218-273X},
	pages = {1-15},
	orcid-numbers = {Szántó, Sándor Zoltán/0000-0001-5030-6292}
}

@article{MTMT:32440947,
	title = {Associations of vascular and bone status in arthritis patients},
	url = {https://m2.mtmt.hu/api/publication/32440947},
	author = {Karancsiné Pusztai, Anita and Hamar, Attila and Czókolyová, Monika and Gulyás, Katalin and Horváth, Ágnes and Vegh, Edit and Pethő, Zsófia and Szamosi, Szilvia and Balogh, Emese and Bodnár, Nóra and Bodoki, Levente and Szentpetery, Agnes and Bhattoa Harjit, Pál and Kerekes, György and Juhász, Balázs and Szekanecz, Éva and Hodosi, Katalin and Domjan, Andrea and Szántó, Sándor Zoltán and Raterman, Hennie G. and Lems, Willem F. and Szekanecz, Zoltán and Szűcs, Gabriella},
	doi = {10.1038/s41598-021-99071-9},
	journal-iso = {SCI REP},
	journal = {SCIENTIFIC REPORTS},
	volume = {11},
	unique-id = {32440947},
	issn = {2045-2322},
	abstract = {Cardiovascular (CV) disease and osteoporosis (OP) have been associated with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Bone and vascular biomarkers and parameters along with the effect of 1-year anti-TNF therapy on these markers were assessed in order to determine correlations between vascular pathophysiology and bone metabolism in RA and AS. Thirty-six patients treated with etanercept or certolizumab pegol and 17 AS patients treated with ETN were included in a 12-month follow-up study. Bone and vascular markers were previously assessed by ELISA. Bone density was measured by DXA and quantitative CT (QCT). Flow-mediated vasodilation (FMD), common carotid intima-media thickness (IMT) and pulse-wave velocity (PWV) were assessed by ultrasound. Multiple correlation analyses indicated associations between bone and vascular markers. Osteoprotegerin, sclerostin and cathepsin K were significantly associated with FMD, IMT and PWV, respectively (p < 0.05). Moreover, total and trabecular BMD determined by QCT inversely correlated with IMT (p < 0.05). On the other hand, among vascular parameters, platelet-derived growth factor BB and IMT correlated with DXA femoral and QCT total BMD, respectively (p < 0.05). In the RM-ANOVA analysis, anti-TNF treatment together with baseline osteocalcin, procollagen 1 N-terminal propeptide (P1NP) or vitamin D3 levels determined one-year changes in IMT (p < 0.05). In the MANOVA analysis, baseline disease activity indices (DAS28, BASDAI), the one-year changes in these indices, as well as CRP exerted effects on multiple correlations between bone and vascular markers (p < 0.05). As the pattern of interactions between bone and vascular biomarkers differed between baseline and after 12 months, anti-TNF therapy influenced these associations. We found a great number of correlations in our RA and AS patients undergoing anti-TNF therapy. Some of the bone markers have been associated with vascular pathophysiology, while some vascular markers correlated with bone status. In arthritis, systemic inflammation and disease activity may drive both vascular and bone disease.},
	year = {2021},
	eissn = {2045-2322},
	orcid-numbers = {Bhattoa Harjit, Pál/0000-0002-4909-0065; Szántó, Sándor Zoltán/0000-0001-5030-6292}
}

@article{MTMT:32274642,
	title = {Peripheral quantitative computed tomography in the assessment of bone mineral density in anti-TNF-treated rheumatoid arthritis and ankylosing spondylitis patients},
	url = {https://m2.mtmt.hu/api/publication/32274642},
	author = {Juhász, Balázs and Gulyás, Katalin and Horvath, Agnes and Vegh, Edit and Karancsiné Pusztai, Anita and Szentpetery, Agnes and Pethő, Zsófia and Bodnár, Nóra and Hamar, Attila and Bodoki, Levente and Bhattoa Harjit, Pál and Szekanecz, Éva and Hodosi, Katalin and Domjan, Andrea and Szamosi, Szilvia and Horváth, Csaba and Szántó, Sándor Zoltán and Szűcs, Gabriella and Raterman, Hennie G. and Lems, Willem F. and FitzGerald, Oliver and Szekanecz, Zoltán},
	doi = {10.1186/s12891-021-04708-5},
	journal-iso = {BMC MUSCULOSKEL DIS},
	journal = {BMC MUSCULOSKELETAL DISORDERS},
	volume = {22},
	unique-id = {32274642},
	issn = {1471-2474},
	abstract = {Introduction Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are associated with osteoporosis. There have not been many peripheral quantitative computed tomography (QCT) studies in patients receiving biologics. We assessed volumetric and areal bone mineral density (BMD) by forearm QCT and dual-energy X-ray absorptiometry (DXA), respectively in addition to laboratory biomarkers in these arthritides. Methods Forty RA and AS patients treated with either etanercept (ETN) or certolizumab pegol (CZP) were undergoing follow-ups for one year. Volumetric and areal BMD, as well as parathyroid hormone (PTH), osteocalcin, RANKL, 25-hydroxyvitamin D (VITD), P1NP, CTX, sclerostin (SOST), Dickkopf 1 (DKK-1) and cathepsin K (CATHK) were determined. Results We did not observe any further bone loss during the 12-month treatment period. Volumetric and areal BMD showed significant correlations with each other (p<0.017 after Bonferroni's correction). Trabecular QCT BMD at baseline (p=0.015) and cortical QCT BMD after 12 months (p=0.005) were inversely determined by disease activity at baseline in the full cohort. Trabecular QCT BMD at baseline also correlated with CTX (p=0.011). In RA, CRP negatively (p=0.014), while SOST positively (p=0.013) correlated with different QCT parameters. In AS, RANKL at baseline (p=0.014) and after 12 months (p=0.007) correlated with cortical QCT BMD. In the full cohort, 12-month change in QTRABBMD was related to TNF inhibition together with elevated VITD-0 levels (p=0.031). Treatment and lower CATHK correlated with QCORTBMD changes (p=0.006). In RA, TNF inhibition together with VITD-0 (p<0.01) or CATHK-0 (p=0.002), while in AS, treatment and RANKL-0 (p<0.05) determined one-year changes in QCT BMD. Conclusions BMD as determined by QCT did not change over one year of anti-TNF treatment. Disease activity, CATHK, RANKL and VITD may be associated with the effects of anti-TNF treatment on QCT BMD changes. RA and AS may differ in this respect.},
	keywords = {Bone Density; osteoporosis; rheumatoid arthritis; ankylosing spondylitis; Biologics; Peripheral quantitative computed tomography},
	year = {2021},
	eissn = {1471-2474},
	orcid-numbers = {Bhattoa Harjit, Pál/0000-0002-4909-0065; Horváth, Csaba/0000-0002-0490-7932; Szántó, Sándor Zoltán/0000-0001-5030-6292}
}